Based on findings from the GENERATION HD1 study in adults with manifest HD, Roche has announced that the tominersen research program will continue with a new Phase II trial.
Two information sessions have been scheduled to provide more information. See details below.
Huntington’s Disease Society of America
Thursday 20th January at 3pm (Eastern Time – US and Canada) https://hdsa.org/hd-research/hdsa-research-webinars/
European Huntington’s Association
Monday 24th January at 6pm (Central European Time) http://eurohuntington.org/2022/01/10/generation-hd1-what-does-the-data-tell-us/